Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.58 |
| ▸ | FNTB | P49356 | 3/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484493 | 0.85 | FNTA (0.58) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL6477825 | 0.85 | FNTA (0.58) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL3865512 | 0.81 | MAOB (0.77) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL28185508 | 0.81 | MAOB (0.58) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL3236287 | 0.80 | SLC2A1 (0.52) | — | |
| SCHEMBL15831939 | 0.80 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL551837 | 0.80 | FFAR1 (0.67) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL3319334 | 0.80 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL2700393 | 0.80 | MAOB (0.56) | FNTAFNTBPGGT1BMAOBFFAR1 | |
| SCHEMBL23706506 | 0.80 | MAPK1 (0.51) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| WO-1996025426-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | FNTA 1089/4885FNTB 915/4885PGGT1B 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.